NASDAQ-listed Iovance Biotherapeutics Discloses Inducement Awards under Rule 5635(c)(4)
Iovance Biotherapeutics, Inc., a leading biotechnology company focused on developing novel TIL therapies for cancer patients, has announced the grant of stock options to two new, non-executive employees on September 18, 2025.
The press release, issued by the company, contains forward-looking statements made by Iovance Biotherapeutics, Inc. It is important to note that these statements are not guarantees of future performance and actual results may materially differ from those expressed or implied by these forward-looking statements.
The stock options were granted under the Amended and Restated 2021 Inducement Plan. Each stock option has an exercise price of $2.20, the closing price of Iovance's common stock on the Date of Grant. The stock options vest over a three-year period with one-third vesting on the first anniversary of the employee's start date and the remaining shares vesting in eight quarterly installments over the next two years.
Iovance is committed to continuous innovation in cell therapy, including gene-edited cell therapy. This commitment is reflected in the grant of stock options to these new employees, who will play a crucial role in the company's mission to be the global leader in TIL therapies for cancer.
Investor inquiries can be directed to [email protected] or 650-260-7120 ext. 150. Media inquiries can be directed to [email protected] or the same phone number.
It is worth mentioning that Amtagvi®, Proleukin®, Iovance®, and IovanceCaresTM are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries.
The company's TIL platform has demonstrated promising clinical data across multiple solid tumors, making Amtagvi®, the first FDA-approved T cell therapy for a solid tumor indication from Iovance Biotherapeutics, Inc., a significant milestone in the fight against cancer.
However, it is important to consider the "Risk Factors" sections of Iovance's filings with the U.S. Securities and Exchange Commission, as important factors that could cause actual results to differ are described therein. The press release does not undertake any duty to update or revise any such statements.
In conclusion, the grant of stock options to these new employees marks a significant step forward for Iovance Biotherapeutics, Inc. as they continue to innovate and push the boundaries of cell therapy for the benefit of cancer patients worldwide.
Read also:
- County Hall's grand display pays tribute to compassionate family members - County administration lauds loving relatives
- Grains of contemporary wheat now offer fewer essential nutrients
- Uncovered: The First Genetic Analysis of Sweet Potatoes Reveals They Originated as Hybrid Species with a Perplexing History and Six Sets of Chromosomes
- Experience the Variety of Wellness Offered by Jasmine Tea
(4)){kind=link}